• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研制新型普瑞巴林控释片:犬和人体内的制剂变化及药代动力学。

Development of a Novel Controlled-Release Tablet of Pregabalin: Formulation Variation and Pharmacokinetics in Dogs and Humans.

机构信息

College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.

GL PharmTech Corp, Seongnam, Republic of Korea.

出版信息

Drug Des Devel Ther. 2020 Jan 30;14:445-456. doi: 10.2147/DDDT.S222505. eCollection 2020.

DOI:10.2147/DDDT.S222505
PMID:32099329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6996546/
Abstract

BACKGROUND

Novel three-layered (TL) tablet systems were compared with both monolithic matrix (MM) formulations and a commercial immediate-release (IR) capsule to develop once-a-day (OAD) pregabalin tablets.

METHODS

The physical properties of the TL tablets, including dissolution and swelling rates, were compared with those of the MM tablets and the pharmacokinetic parameters of the TL tablet were compared with those of an IR capsule in beagles and humans.

RESULTS

Our results indicated that the same amount of a hydrophilic polymer in the formulations had similar dissolution profiles at 12 h, regardless of the tablet geometry. However, the degree of tablet swelling differed, with larger amounts of polymer in the tablets showing a greater degree of swelling. In addition, TL tablets swelled more rapidly compared with MM tablets. For the pharmacokinetic study of the TL tablet, the beagles demonstrated absorption results similar to those of an IR capsule, whereas the humans demonstrated low total absorption compared with an IR capsule. The time of the peak plasma concentration at 6 h in the fed state of humans coincided with the results of the study on beagles.

CONCLUSION

The novel TL tablet system of pregabalin may prove to be helpful in developing improved formulations with better continuous drug absorption for OAD administration.

摘要

背景

新型三层(TL)片剂系统与单片基质(MM)制剂和一种商业即时释放(IR)胶囊进行了比较,以开发每日一次(OAD)普瑞巴林片剂。

方法

TL 片剂的物理性质,包括溶出度和溶胀率,与 MM 片剂进行了比较,TL 片剂的药代动力学参数与比格犬和人体内的 IR 胶囊进行了比较。

结果

我们的结果表明,在 12 小时时,制剂中相同量的亲水性聚合物具有相似的溶出曲线,而不管片剂的几何形状如何。然而,片剂的溶胀程度不同,片剂中聚合物的含量越多,溶胀程度越大。此外,TL 片剂比 MM 片剂膨胀得更快。对于 TL 片剂的药代动力学研究,比格犬的吸收结果与 IR 胶囊相似,而人体与 IR 胶囊相比总吸收较低。在人体进食状态下,6 小时时的血浆峰浓度时间与比格犬的研究结果一致。

结论

新型普瑞巴林 TL 片剂系统可能有助于开发更好的制剂,以改善 OAD 给药的持续药物吸收。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/b045ac73e04c/DDDT-14-445-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/3675be083909/DDDT-14-445-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/876914f6eb2e/DDDT-14-445-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/2def9dcdaba7/DDDT-14-445-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/1fe8f4dc1d46/DDDT-14-445-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/57b13ed4e9a2/DDDT-14-445-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/8bda8fddbe89/DDDT-14-445-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/0855e912a5ca/DDDT-14-445-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/b045ac73e04c/DDDT-14-445-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/3675be083909/DDDT-14-445-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/876914f6eb2e/DDDT-14-445-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/2def9dcdaba7/DDDT-14-445-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/1fe8f4dc1d46/DDDT-14-445-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/57b13ed4e9a2/DDDT-14-445-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/8bda8fddbe89/DDDT-14-445-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/0855e912a5ca/DDDT-14-445-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d12f/6996546/b045ac73e04c/DDDT-14-445-g0008.jpg

相似文献

1
Development of a Novel Controlled-Release Tablet of Pregabalin: Formulation Variation and Pharmacokinetics in Dogs and Humans.研制新型普瑞巴林控释片:犬和人体内的制剂变化及药代动力学。
Drug Des Devel Ther. 2020 Jan 30;14:445-456. doi: 10.2147/DDDT.S222505. eCollection 2020.
2
Preparation and evaluation of non-effervescent gastroretentive tablets containing pregabalin for once-daily administration and dose proportional pharmacokinetics.制备和评价含有普瑞巴林的非泡腾型胃滞留片用于每日一次给药和剂量比例药代动力学。
Int J Pharm. 2018 Oct 25;550(1-2):160-169. doi: 10.1016/j.ijpharm.2018.08.038. Epub 2018 Aug 20.
3
Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation.设计和优化普瑞巴林胃漂浮型缓释片:体外和体内评价。
Int J Pharm. 2018 Jul 10;545(1-2):37-44. doi: 10.1016/j.ijpharm.2018.04.011. Epub 2018 Apr 9.
4
Comparative Pharmacokinetics of a Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and an Immediate-release Pregabalin Capsule in Healthy Male Volunteers.健康男性志愿者中控释型普瑞巴林片剂(GLA5PR GLARS-NF1)与即释型普瑞巴林胶囊的比较药代动力学。
Clin Ther. 2018 Dec;40(12):2112-2124. doi: 10.1016/j.clinthera.2018.10.017. Epub 2018 Nov 27.
5
Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate.使用山嵛酸甘油酯热熔包衣法制备缓释普瑞巴林片。
Int J Pharm. 2015 Nov 10;495(1):1-8. doi: 10.1016/j.ijpharm.2015.08.057. Epub 2015 Aug 24.
6
Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies.健康志愿者中普瑞巴林控释制剂的药代动力学:四项多剂量随机临床药理学研究分析
Clin Drug Investig. 2014 Sep;34(9):627-37. doi: 10.1007/s40261-014-0221-2.
7
Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl.盐酸坦索罗辛速溶三层片的制剂变化及体内外相关性
Chem Pharm Bull (Tokyo). 2011;59(5):529-35. doi: 10.1248/cpb.59.529.
8
A novel three-layered tablet for extended release with various layer formulations and in vitro release profiles.一种具有各种层配方和体外释放曲线的新型三层缓释片剂。
Drug Dev Ind Pharm. 2011 Jun;37(6):664-72. doi: 10.3109/03639045.2010.535211. Epub 2011 Mar 30.
9
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.生物豁免扩展至生物药剂学分类系统III类药品的可行性:西咪替丁
Clin Pharmacokinet. 2006;45(4):385-99. doi: 10.2165/00003088-200645040-00004.
10
In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.茶碱基质片和新型簇片的体外及体内缓释特性
Int J Pharm. 2007 Aug 16;341(1-2):105-13. doi: 10.1016/j.ijpharm.2007.03.048. Epub 2007 Apr 5.

引用本文的文献

1
Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin.在哺乳期和药物暴露相关的风险评估中:普瑞巴林的基于生理的药代动力学哺乳模型。
CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1953-1966. doi: 10.1002/psp4.13266. Epub 2024 Oct 26.
2
Delirium After Pregabalin Withdrawal.普瑞巴林撤药后出现的谵妄
Alpha Psychiatry. 2021 Mar 18;22(2):118-119. doi: 10.5455/apd.117770. eCollection 2021 Mar.
3
An Integrative QbD Approach for the Development and Optimization of Controlled Release Compressed Coated Formulation of Water-Soluble Drugs.

本文引用的文献

1
Preparation and evaluation of floating tablets of pregabalin.普瑞巴林胃内漂浮片的制备与评价
Drug Dev Ind Pharm. 2016;42(4):654-60. doi: 10.3109/03639045.2015.1062895. Epub 2015 Jul 6.
2
Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies.健康志愿者中普瑞巴林控释制剂的药代动力学:四项多剂量随机临床药理学研究分析
Clin Drug Investig. 2014 Sep;34(9):627-37. doi: 10.1007/s40261-014-0221-2.
3
Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.
一种用于开发和优化水溶性药物控释压缩包衣制剂的综合质量源于设计方法
AAPS PharmSciTech. 2022 Apr 22;23(5):120. doi: 10.1208/s12249-022-02225-9.
4
The Effects of Prenatal Exposure to Pregabalin on the Development of Ventral Midbrain Dopaminergic Neurons.产前暴露于普瑞巴林对腹侧中脑多巴胺能神经元发育的影响。
Cells. 2022 Mar 1;11(5):852. doi: 10.3390/cells11050852.
5
Pathogenic Mechanism of Dry Eye-Induced Chronic Ocular Pain and a Mechanism-Based Therapeutic Approach.干眼导致慢性眼部疼痛的发病机制及基于机制的治疗方法。
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):7. doi: 10.1167/iovs.63.1.7.
6
Preclinical Evaluation of Polymeric Nanocomposite Containing Pregabalin for Sustained Release as Potential Therapy for Neuropathic Pain.含普瑞巴林的聚合物纳米复合材料用于持续释放的临床前评估:作为神经性疼痛潜在疗法的研究
Polymers (Basel). 2021 Nov 6;13(21):3837. doi: 10.3390/polym13213837.
普瑞巴林控释制剂在健康志愿者中的药代动力学:五项单剂量、随机临床药理学研究中食物的影响
Clin Drug Investig. 2014 Sep;34(9):617-26. doi: 10.1007/s40261-014-0211-4.
4
Evaluation of drug delivery profiles in geometric three-layered tablets with various mechanical properties, in vitro-in vivo drug release, and Raman imaging.评估具有不同机械性能的几何三层片剂中的药物递送曲线、体外-体内药物释放和拉曼成像。
J Control Release. 2013 Dec 28;172(3):763-72. doi: 10.1016/j.jconrel.2013.08.301. Epub 2013 Sep 12.
5
Applications of poly(ethylene oxide) in controlled release tablet systems: a review.聚环氧乙烷在控释片剂系统中的应用:综述
Drug Dev Ind Pharm. 2014 Jul;40(7):845-51. doi: 10.3109/03639045.2013.831438. Epub 2013 Sep 3.
6
Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet.放射性药物闪烁照相术证实新型三层片剂能持续释放坦索罗辛。
Int J Pharm. 2013 Sep 15;454(1):41-6. doi: 10.1016/j.ijpharm.2013.06.065. Epub 2013 Jul 5.
7
Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis.降低给药频率对口服治疗依从性的影响:一项文献综述与荟萃分析。
Patient Prefer Adherence. 2013 May 20;7:419-34. doi: 10.2147/PPA.S44646. Print 2013.
8
Dosing frequency and medication adherence in chronic disease.慢性病中的给药频率与药物依从性
J Manag Care Pharm. 2012 Sep;18(7):527-39. doi: 10.18553/jmcp.2012.18.7.527.
9
A novel three-layered tablet for extended release with various layer formulations and in vitro release profiles.一种具有各种层配方和体外释放曲线的新型三层缓释片剂。
Drug Dev Ind Pharm. 2011 Jun;37(6):664-72. doi: 10.3109/03639045.2010.535211. Epub 2011 Mar 30.
10
A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.比较普瑞巴林和加巴喷丁的药代动力学和药效学。
Clin Pharmacokinet. 2010 Oct;49(10):661-9. doi: 10.2165/11536200-000000000-00000.